AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

Wednesday, 21 December 2011

London, Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib, which will imminently enter Phase I testing, has been discovered and developed in China by HMP.

Read full announcement here

Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar